max marchione

T2 · manager / operator

Australian-born founder who solved his own decade-long misdiagnosis at 18 via '10X doctor.' Founded Superpower 3 years ago to democratize frontier medicine via AI-first health platform. Raised $40M Series A, growing thousands of members/month. Building digital twin, AI clinical reasoning, and full-stack action layer.

6 calls·6 names·33% bull·last heard 7 months ago·Antonio Linares
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1sthigh conviction
$SUPERPOWERSuperpowerposition

Superpower raises $40M Series A, growing thousands of members/month with AI-first health platform

Superpower builds AI-first health platform with 100+ biomarker testing ($199), digital twin, AI clinical reasoning (ensemble models + proprietary clinical canon), and action layer (supplements, pharmaceuticals, peptides). Growing via word-of-mouth with 93% members rating AI report far better than primary care. Planning Series B mid-2025.

2ndhigh conviction
$NVONovo Nordisk

Novo Nordisk and Eli Lilly will own future patented GLP-1 classes, making compounding risky long-term

Future GLP-1 generations will be patented by Eli Lilly and Novo Nordisk with defensible IP, making current compounding bets risky long-term despite short-term viability. The next wave of GLP-1s will have improved delivery, absorption, duration and side effect profiles protected by patents.

3rdhigh conviction
$HIMSHims & Hers Health

Max Marchione analyzes Hims' e-commerce strategy vs Superpower's tech-first approach

Hims follows a CPG/e-commerce path (fastest to revenue/gross profit) but lacks lifestyle brand and tech layer; Superpower takes product-first tech approach with stronger retention and platform dynamics. The winner depends on whether incumbent gets innovation before startup gets distribution.

6 total
$NVO
···
Novo Nordisk
HIGHmax marchione·Antonio Linares·7 months ago
Novo Nordisk and Eli Lilly will own future patented GLP-1 classes, making compounding risky long-term
Future GLP-1 generations will be patented by Eli Lilly and Novo Nordisk with defensible IP, making current compounding bets risky long-term despite short-term viability. The next wave of GLP-1s will have improved delivery, absorption, duration and side effect profiles protected by patents.
"I think most future classes of GLP1s will be owned by Eli Novo. Hims is making a really, really big bet compounding. Not because it's risky in the short term... It's risky in the…"
17:36
$SUPERPOWER
Superpower
HIGHmax marchione·Antonio Linares·7 months ago· position
Superpower raises $40M Series A, growing thousands of members/month with AI-first health platform
Superpower builds AI-first health platform with 100+ biomarker testing ($199), digital twin, AI clinical reasoning (ensemble models + proprietary clinical canon), and action layer (supplements, pharmaceuticals, peptides). Growing via word-of-mouth with 93% members rating AI report far better than primary care. Planning Series B mid-2025.
"We're around two years in. We removed the weight list in August uh this year and now we're adding thousands and thousands of new members a month... for $199 a year, we'll say, 'Le…"
4:55
$STEALTH-BIOSCIENCES
Stealth Biosciences
LOWmax marchione·Antonio Linares·7 months ago
Stealth Biosciences owns SS31 mitochondrial peptide, enforcing IP against unauthorized sellers
Stealth Biosciences holds IP on SS31 (mitochondrial peptide for longevity/energy) and actively sends cease-and-desist letters to unauthorized sellers, indicating defensible patent position in emerging peptide market.
"We're seeing all sorts of companies introduce new delivery mechanisms... Stealth Biosciences owns SS31. They're sending cease and assists to everyone selling that right now. SS31…"
18:51
$HIMS
···
Hims & Hers Health
HIGHmax marchione·Antonio Linares·7 months ago
Max Marchione analyzes Hims' e-commerce strategy vs Superpower's tech-first approach
Hims follows a CPG/e-commerce path (fastest to revenue/gross profit) but lacks lifestyle brand and tech layer; Superpower takes product-first tech approach with stronger retention and platform dynamics. The winner depends on whether incumbent gets innovation before startup gets distribution.
"If I look at HIMS, the path is basically the e-commerce or the CPG path. Pick a skew for which you can acquire users very effectively and cheaply via paid ads. In time, add a litt…"
10:20
$OPENAI
OpenAI
HIGHmax marchione·Antonio Linares·7 months ago
ChatGPT Health is a 'nothing burger' but ChatGPT remains formidable as potential health demand aggregator
ChatGPT Health launch adds nothing new (just a tab) since ChatGPT already captures health queries, wants user context, and moves into action layer. However, ChatGPT could become the ultimate health demand aggregator, forcing companies to become perfect supply aggregators (lowest cost, vertically integrated) to win referred traffic.
"CHGBT health is a nothing burger, right? And the reason why it's a nothing burger is that it's nothing new... We already know one that chubt wants to gather as much context than y…"
38:59
$LLY
···
Eli Lilly
MEDmax marchione·Antonio Linares·7 months ago
Eli Lilly potentially undervalued but needs Pharma 2.0 transformation to own patient relationship
Eli Lilly could be underpriced despite trillion-dollar valuation, but must transition from Pharma 1.0 (disease drugs via payers/health systems) to Pharma 2.0 (wellness drugs direct-to-consumer). Without owning longitudinal patient data and consumer experience, they risk losing the wellness market to companies like Hims or Superpower.
"I publicly am interested in biotech companies developing peptides... there's a world where Eli Liy is still underpriced... I think companies that are making a bet on brand and ver…"
44:09